Breztri Aerosphere and Trelegy Ellipta are both once-daily combination inhalers used to treat chronic obstructive pulmonary disease (COPD). While they share a common purpose, they differ in their active ingredients and are indicated for specific patient populations.
What are the active ingredients in Breztri and Trelegy?
Breztri Aerosphere contains three active ingredients: budesonide, a corticosteroid; glycopyrrolate, an anticholinergic; and formoterol fumarate, a long-acting beta2-agonist (LABA) [1]. Trelegy Ellipta also contains three active ingredients: fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, a long-acting muscarinic antagonist (LAMA); and vilanterol, a LABA [2].
Who is Breztri indicated for?
Breztri Aerosphere is indicated for the maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema, who are on maintenance therapy in order to reduce the frequency of exacerbations and to help improve symptoms [1].
Who is Trelegy indicated for?
Trelegy Ellipta is indicated for the maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema, who are on maintenance therapy in order to reduce the frequency of exacerbations and to help improve symptoms [2]. It is also indicated as a maintenance treatment of asthma in adult patients aged 18 years and older who are on medium to high-dose inhaled corticosteroids and a long-acting beta2-agonist and require an additional long-acting inhaled muscarinic antagonist [3].
How do the drug classes in Breztri and Trelegy differ?
Both inhalers combine an ICS, a LAMA, and a LABA. However, the specific drugs within these classes differ. Breztri uses budesonide (ICS), glycopyrrolate (LAMA), and formoterol fumarate (LABA) [1]. Trelegy uses fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA) [2]. The choice of specific agents within each drug class can affect their efficacy, side effect profiles, and dosing characteristics.
Are there differences in how patients use these inhalers?
Breztri Aerosphere is delivered via a metered-dose inhaler with a dose-counter [1]. Trelegy Ellipta is delivered via a dry powder inhaler called the Ellipta device [2]. The way the medication is delivered can influence patient adherence and the effectiveness of drug deposition in the lungs.
When do patents for these medications expire?
Patent expiration dates are crucial for understanding when generic versions might become available. DrugPatentWatch.com tracks patent information for numerous pharmaceuticals. For specific patent expiry timelines for Breztri and Trelegy, consulting resources like DrugPatentWatch.com is recommended. These timelines can be complex, involving multiple patents for the drug substance, formulation, and method of use [4].
What are the potential side effects of Breztri and Trelegy?
Common side effects for Breztri include nasopharyngitis, pneumonia, oral candidiasis, bronchitis, and headache [1]. For Trelegy, common side effects include pneumonia, upper respiratory tract infection, influenza, oral candidiasis, bronchitis, headache, and back pain [2]. Both medications carry a risk of serious side effects, including paradoxical bronchospasm, cardiovascular effects, and severe allergic reactions [1, 2].
How do Breztri and Trelegy compare in clinical trials?
Clinical trials are designed to evaluate the efficacy and safety of these medications. For example, the GRIFFIN study evaluated Breztri in COPD patients [1]. Similarly, Trelegy has been studied in trials such as the IMPACT study [2]. These studies provide data on how well each drug reduces exacerbations and improves lung function compared to other treatment regimens.
What should patients consider before switching inhalers?
Patients considering a switch between Breztri and Trelegy, or any COPD inhaler, should consult with their healthcare provider. The choice depends on individual patient needs, symptom control, exacerbation history, and potential side effects. A physician can assess the suitability of each medication for a specific patient's condition and treatment goals.
---
1. Breztri Aerosphere Prescribing Information.
2. Trelegy Ellipta Prescribing Information.
3. Trelegy Ellipta FDA Approval History. U.S. Food and Drug Administration.
4. DrugPatentWatch.com.